Alexandre Puissant

5.2k total citations · 1 hit paper
59 papers, 3.1k citations indexed

About

Alexandre Puissant is a scholar working on Molecular Biology, Hematology and Genetics. According to data from OpenAlex, Alexandre Puissant has authored 59 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Molecular Biology, 28 papers in Hematology and 14 papers in Genetics. Recurrent topics in Alexandre Puissant's work include Acute Myeloid Leukemia Research (19 papers), Chronic Myeloid Leukemia Treatments (13 papers) and Chronic Lymphocytic Leukemia Research (11 papers). Alexandre Puissant is often cited by papers focused on Acute Myeloid Leukemia Research (19 papers), Chronic Myeloid Leukemia Treatments (13 papers) and Chronic Lymphocytic Leukemia Research (11 papers). Alexandre Puissant collaborates with scholars based in France, United States and Sweden. Alexandre Puissant's co-authors include Patrick Auberger, Guillaume Robert, Nina Fenouille, Frédéric Luciano, Jill‐Patrice Cassuto, Sophie Raynaud, Arnaud Jacquel, Pascal Colosetti, Kimberly Stegmaier and Gabriela Alexe and has published in prestigious journals such as Nature Genetics, Blood and PLoS ONE.

In The Last Decade

Alexandre Puissant

57 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition

2013 457 citations Alexandre Puissant, Stacey M. Frumm et al. Cancer Discovery profile →

Peers

Countries citing papers authored by Alexandre Puissant

Since Specialization

Citations

This map shows the geographic impact of Alexandre Puissant's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alexandre Puissant with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alexandre Puissant more than expected).

Fields of papers citing papers by Alexandre Puissant

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alexandre Puissant. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alexandre Puissant. The network helps show where Alexandre Puissant may publish in the future.

Co-authorship network of co-authors of Alexandre Puissant

This figure shows the co-authorship network connecting the top 25 collaborators of Alexandre Puissant. A scholar is included among the top collaborators of Alexandre Puissant based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alexandre Puissant. Alexandre Puissant is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	INA03: A Potent Transferrin-Competitive Antibody–Drug Conjugate against CD71 for Safer Acute Leukemia Treatment 2024 ·Molecular Cancer Therapeutics ·(unknown), (unknown), Sergii Kolodych, (unknown), (unknown), (unknown), (unknown), Rémy Castellano, Emmanuelle Josselin, (unknown), Lina Benajiba, Alexandre Puissant, Oleksandr Koniev, Yves Collette, Coralie Bélanger, Olivier Hermine, Renato C. Monteiro, Pierre Launay	1
2	Failure to Execute Caspase Activation Drives Therapy Resistance in TP53 Mutated AML 2024 ·Blood ·(unknown), (unknown), Yang Mi, (unknown), Yichen Wang, (unknown), (unknown), (unknown), (unknown), Philipp Mertins, (unknown), Yihua Qiu, (unknown), Alexandre Puissant, Steven M. Kornblau, Jan Krönke, Edward Ayoub, Koji Itahana, (unknown), Shruti Bhatt	0
3	Screening of ETO2-GLIS2–induced Super Enhancers identifies targetable cooperative dependencies in acute megakaryoblastic leukemia 2022 ·Science Advances ·Salima Benbarche, Cécile K. Lopez, Eralda Salataj, (unknown), Cécile Thirant, Marie-Charlotte Laiguillon, Séverine Lecourt, (unknown), (unknown), (unknown), Jiang Hu, (unknown), Delphine Ndiaye‐Lobry, (unknown), Arnaud Petit, Alexandre Puissant, Julie Chaumeil, Thomas Mercher, Camille Lobry	9
4	Phosphoproteomics of primary AML patient samples reveals rationale for AKT combination therapy and p53 context to overcome selinexor resistance 2022 ·Cell Reports ·Kristina B. Emdal, Nicolàs Palacio‐Escat, Caroline Wigerup, (unknown), Helén Nilsson, Dorte B. Bekker‐Jensen, Lars Rönnstrand, Julhash U. Kazi, Alexandre Puissant, Raphaël Itzykson, Julio Sáez-Rodríguez, Kristina Masson, Peter Blume‐Jensen, Jesper V. Olsen	21
5	Targeting serine hydroxymethyltransferases 1 and 2 for T-cell acute lymphoblastic leukemia therapy 2021 ·Leukemia ·Yana Pikman, (unknown), Gabriela Alexe, Boris Dimitrov, (unknown), Frances F. Diehl, Amanda L. Robichaud, Amy Saur Conway, Linda S. Ross, Angela Su, (unknown), Jun Qi, Giovanni Roti, Caroline A. Lewis, Alexandre Puissant, Matthew G. Vander Heiden, Kimberly Stegmaier	36
6	Using antagonistic pleiotropy to design a chemotherapy-induced evolutionary trap to target drug resistance in cancer 2020 ·Nature Genetics ·Kevin Lin, Justine C. Rutter, Abigail Xie, (unknown), (unknown), (unknown), Antoine Forget, Raphaël Itzykson, Lucie Ahn, Ziwei Dai, (unknown), Grace R. Anderson, Katherine R. Singleton, Amy E. Decker, Peter Winter, Jason W. Locasale, Lorin Crawford, Alexandre Puissant, Kris C. Wood	39
7	Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML 2016 ·Oncogene ·(unknown), Eugenia Cordero, Alexandre Puissant, (unknown), (unknown), (unknown), Jianmin Sun, Johan Vallon‐Christersson, Karin Haraldsson, Michael T. Hemann, Åke Borg, Fredrik Levander, Kimberly Stegmaier, Kristian Pietras, Lars Rönnstrand, Julhash U. Kazi	96
8	SYK Is a Critical Regulator of FLT3 in Acute Myeloid Leukemia 2014 ·Cancer Cell ·Alexandre Puissant, Nina Fenouille, Gabriela Alexe, Yana Pikman, Christopher F. Bassil, Swapnil Mehta, Jinyan Du, Julhash U. Kazi, Frédéric Luciano, Lars Rönnstrand, Andrew L. Kung, Jon C. Aster, Ilene Galinsky, Richard M. Stone, Daniel J. DeAngelo, Michael T. Hemann, Kimberly Stegmaier	109
9	Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition breakdown → 2013 ·Cancer Discovery ·Alexandre Puissant, Stacey M. Frumm, Gabriela Alexe, Christopher F. Bassil, Jun Qi, Yvan H. Chanthery, Erin A. Nekritz, Rhamy Zeid, W. Clay Gustafson, Patricia Greninger, Matthew J. Garnett, Ultan McDermott, Cyril H. Benes, Andrew L. Kung, William A. Weiss, James E. Bradner, Kimberly Stegmaier	457
10	Tumor suppressor function of miR-483-3p on squamous cell carcinomas due to its pro-apoptotic properties 2013 ·Cell Cycle ·Thomas Bertero, Isabelle Bourget, Alexandre Puissant, Agnès Loubat, Bernard Mari, Guerrino Meneguzzi, Patrick Auberger, Pascal Barbry, Gilles Ponzio, Roger Rezzonico	53
11	SYK regulates mTOR signaling in AML 2013 ·Leukemia ·Julia Carnevale, Linda Ross, Alexandre Puissant, Versha Banerji, Richard M. Stone, Daniel J. DeAngelo, Kenneth N. Ross, Kimberly Stegmaier	40
12	The caspase 6 derived N-terminal fragment of DJ-1 promotes apoptosis via increased ROS production 2012 ·Cell Death and Differentiation ·Guillaume Robert, Alexandre Puissant, Maeva Dufies, Sandrine Marchetti, Arnaud Jacquel, Thomas Cluzeau, Pascal Colosetti, Nathalie Belhacène, Philipp J. Kahle, Cristine Alvès da Costa, Frédéric Luciano, Frédéric Checler, Patrick Auberger	20
13	Sestrin2 integrates Akt and mTOR signaling to protect cells against energetic stress-induced death 2012 ·Cell Death and Differentiation ·Issam Ben‐Sahra, Béatrice Dirat, Kathiane Laurent, Alexandre Puissant, Patrick Auberger, Andrei V. Budanov, Jean‐François Tanti, Frédéric Bost	127
14	Structure elucidation of the new citharoxazole from the Mediterranean deep‐sea sponge Latrunculia (Biannulata) citharistae 2011 ·Magnetic Resonance in Chemistry ·Grégory Genta‐Jouve, (unknown), Alexandre Puissant, Patrick Auberger, Jean Vacelet, Thierry Pérez, Angelo Fontana, Ali Al‐Mourabit, Olivier P. Thomas	12
15	Persistent Activation of the Fyn/ERK Kinase Signaling Axis Mediates Imatinib Resistance in Chronic Myelogenous Leukemia Cells through Upregulation of Intracellular SPARC 2010 ·Cancer Research ·Nina Fenouille, Alexandre Puissant, Maeva Dufies, Guillaume Robert, Arnaud Jacquel, Mickaël Ohanna, Marcel Deckert, Jean‐Max Pasquet, François‐Xavier Mahon, Jill‐Patrice Cassuto, Sophie Raynaud, Sophie Tartare‐Deckert, Patrick Auberger	52
16	Resveratrol Promotes Autophagic Cell Death in Chronic Myelogenous Leukemia Cells via JNK-Mediated p62/SQSTM1 Expression and AMPK Activation 2010 ·Cancer Research ·Alexandre Puissant, Guillaume Robert, Nina Fenouille, Frédéric Luciano, Jill‐Patrice Cassuto, Sophie Raynaud, Patrick Auberger	323
17	Ciglitazone negatively regulates CXCL1 signaling through MITF to suppress melanoma growth 2010 ·Cell Death and Differentiation ·Thomas Botton, Alexandre Puissant, Yann Chéli, Tijana Tomić, Sandy Giuliano, Lluís Fajas, Marcel Deckert, J P Ortonne, Corine Bertolotto, Sophie Tartare‐Deckert, Robert Ballotti, Stéphane Rocchi	30
18	Targeting autophagy to fight hematopoietic malignancies 2010 ·Cell Cycle ·Alexandre Puissant, Guillaume Robert, Patrick Auberger	61
19	Gene expression profiling of imatinib and PD166326-resistant CML cell lines identifies Fyn as a gene associated with resistance to BCR-ABL inhibitors 2009 ·Molecular Cancer Therapeutics ·Sébastien Grosso, Alexandre Puissant, Maeva Dufies, Pascal Colosetti, Arnaud Jacquel, Kévin Lebrigand, Pascal Barbry, Marcel Deckert, (unknown), Bernard Mari, Patrick Auberger	67
20	Inhibition of imatinib-mediated apoptosis by the caspase-cleaved form of the tyrosine kinase Lyn in chronic myelogenous leukemia cells 2009 ·Leukemia ·Pascal Gamas, Sandrine Marchetti, Alexandre Puissant, Sébastien Grosso, Arnaud Jacquel, Pascal Colosetti, Jean‐Max Pasquet, F-X Mahon, J.P. Cassuto, Patrick Auberger	20

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact